FEB 19, 2014 10:00 AM PST

Next-generation sequencing applications in advanced cancer samples: Experience with Ion AmpliSeq custom panels

Speaker
  • Medical Director of Knight Diagnostic Laboratories Director of Molecular Pathology, Oregon Health & Science University
    Biography
       
      After undergraduate studies at the Univ. of California, Berkeley, Professor Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women's Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University as an Assistant Professor. He has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is an Associate Director of the Oregon Clinical & Translational Research Institute, and he presently serves as Chief Medical Officer for the OHSU Knight Diagnostic Laboratories. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to Professor of Pathology in 2004 and is an author on over 200 publications.
       

    Abstract
    Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are inadequate in the face of the rapidly growing list of genetic mutations that are potentially actionable. This presentation will focus on our experience in designing and running custom Ion AmpliSeq cancer gene panels on the Ion PGM System, an approach we are using to increase the understanding of genetic mutations in advanced cancers. Consideration will be given to detecting mutations of various types, as well as alterations in gene copy number. Critical pre-analytic factors and the integration of other technologies that define clinically significant targets
    for future treatment will also be discussed.

    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    APR 27, 2020 9:00 AM PDT
    C.E. CREDITS
    APR 27, 2020 9:00 AM PDT
    DATE: April 27, 2020 TIME: 9:00am PT, 12:00pm ET Recombinant adeno-associated virus (rAAV) is a small (25-nm) virus that is composed of a protein shell called a capsid and a single-stranded...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    Loading Comments...
    Show Resources